한글목차

심폐 운동 부하 검사(CPET) 시장 규모는 예측 기간 동안 7.25%의 연평균 복합 성장률(CAGR)로 견조한 성장세를 보일 것으로 예상됩니다.

전 세계적으로 심혈관 감염과 폐 고혈압 증가가 이 시장의 성장을 가속하고 있습니다. 심혈관 질환 증가 추세는 인구 고령화, 흡연, 대기오염, 식습관 등 다양한 변수에 기인합니다.

세계 심폐 운동 부하 검사(CPET) 시장을 조사했으며, 시장 정의와 개요, 시장 성장에 영향을 미치는 각종 영향요인 분석, 시장 규모 추이 및 예측, 각종 부문별/지역별 분석, 경쟁 환경, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 주요 요약

제2장 시장 개요

제3장 조사 방법

제4장 시장 역학

• 성장 촉진요인
• 성장 억제요인
• 기회

제5장 시장 영향요인 분석

• 밸류체인 분석
• Porter의 Five Forces 분석
• 시장에 대한 COVID-19의 영향
• 정량적 시장 분석
• 정성적 소비자 평가

제6장 세계의 심폐 운동 부하 시험(CPET) 시장 : 제품별

• CPE 대사 카트
• 소프트웨어

제7장 세계의 심폐 운동 부하 시험(CPET) 시장 : 최종사용자별

• 개요
• 병원 및 진료소
• 진단 센터
• 외래 센터
• 기타

제8장 세계의 심폐 운동 부하 시험(CPET) 시장 : 지역별

• 개요
• 북미
• 유럽
• 아시아태평양
• 기타 지역

제9장 경쟁 구도

• 개요
• 경쟁 벤치마킹
• 주요 성장 전략
• 개발 건수 기준 주요 기업
• 주요 개발 분석
• 주요 발전과 성장 전략
• 재무 매트릭스

제10장 기업 개요

• SCHILLER AG
• COSMED SRL
• MGC DIAGNOSTICS CORPORATION
• OXIGRAF, INC
• VYAIRE MEDICAL, INC
• CORTEX BIOPHYSIK GMBH
• KONINKLIJKE PHILIPS N.V.
• HILL-ROM HOLDINGS, INC
• MEDEV MEDICAL DEVICES CORPORATION
• GERATHERM MEDICAL AG

제11장 부록

영문목차

Cardiopulmonary Exercise Testing Market Research Report Forecast till 2032

Market Overview

Cardiopulmonary Exercise Testing Market is expected to register a healthy CAGR of 7.25% during the forecast period.

The developing pervasiveness of cardiovascular infections like cardiovascular breakdown, and aspiratory hypertension among others across the globe is driving the development of the cardiopulmonary exercise testing market. Cardiopulmonary exercise testing gives important symptomatic data and assists in deciding with practicing limit and utilitarian limits in patients with these circumstances. As per the article distributed by Public Community for Biotechnology Data in June 2022, the test can give both cardiovascular and pneumonic sickness processes, while helping with the advancement of individualized treatment and recovery programs. Also, the rising commonness of cardiovascular sicknesses can be credited to different variables, including maturing populaces, stationary ways of life, smoking, air contamination, and unfortunate eating regimens. As these illnesses progress, they lead to practical impediments, diminished exercise resilience, and hindered cardiopulmonary wellness. In this specific circumstance.

The geriatric populace is more inclined to ongoing infections and grown-ups matured 65 and more seasoned are more probable than more youthful individuals to experience the ill effects of cardiovascular sickness. Maturing can likewise cause a gamble of creating cardiovascular infection. Hence, the rising populace of this part of individuals can likewise build the interest for cardiopulmonary exercise testing to survey a person's cardiovascular and respiratory capabilities.

Accordingly, the developing predominance of cardiovascular illnesses and other constant sicknesses and expanding utilizations of radioisotopes in the medical services industry are energizing market development.

Market Segmentation

The Cardiopulmonary Exercise Testing Market has been divided into two segments based on product type: software and CPET metabolic carts.

The Cardiopulmonary Exercise Testing Market has been divided into ambulatory centers, diagnostic centers, hospitals & clinics, and others based on the end user.

Regional Insights

North America is likely to lead the market owing to a largest market contribution of 37.77% in 2022.

Furthermore, the region's significant development is emphatically impacted by expanding rates of cardiovascular sicknesses (CVD), which increment the interest for cardiopulmonary exercise testing (CPET) programming and CPET metabolic trucks. The CPET metabolic trucks and programming are used in CVDs to offer an assessment of the respiratory, cardiovascular, and skeletal muscle frameworks' coordinated exercise reactions.

The Europe region shows critical development during the forecast time frame. This is because of the rising predominance of persistent sicknesses like cardiovascular illnesses, respiratory problems, and metabolic circumstances that is driving the interest for CPET in Europe. CPET gives important analytic and prognostic data for these circumstances, supporting customized treatment and the board methodologies.

The development of the market in Asia-Pacific is anticipated to rise quickly because of an attributable to high utilizations of CPET in the geriatric populace as maturing populaces are more inclined to CVDs. According to the Asia-Pacific Report on Populace Maturing 2022, there were around 670 million individuals matured 60 or more established in Asia-Pacific in 2022. Besides, the possibilities having CVDs expansion in diabetic patients, which expands the interest for CPET gadgets.

Major Players

Key Companies in the Cardiopulmonary Exercise Testing Market includes Schiller AG, COSMED srl, MGC Diagnostics Corporation, Oxigraf, Inc, Vyaire Medical, Inc, CORTEX Biophysik GmbH, Koninklijke Philips NV, Hill-Rom Holdings, Inc, MEDEV Medical Devices Corporation, Geratherm Medical AG, Schiller AG, COSMED srl, and Others.

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1 OVERVIEW

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE
• 2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

• 3.1 DATA MINING
• 3.2 SECONDARY RESEARCH
• 3.3 PRIMARY RESEARCH
• 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.5 FORECASTING TECHNIQUES
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.6.1 BOTTOM-UP APPROACH
  • 3.6.2 TOP-DOWN APPROACH
• 3.7 DATA TRIANGULATION
• 3.8 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 INCREASE IN THE PREVALENCE OF CARDIOVASCULAR DISEASES
  • 4.2.2 RISING GERIATRIC POPULATION
• 4.3 RESTRAINTS
  • 4.3.1 LACK OF SKILLED AND EXPERIENCED PROFESSIONALS
• 4.4 OPPORTUNITIES
  • 4.4.1 GROWING NUMBER OF STRATEGIC INITIATIVES

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 R&D & DESIGNING
  • 5.1.2 MANUFACTURING
  • 5.1.3 DISTRIBUTION & SALES
  • 5.1.4 POST-SALES MONITORING
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 THREAT OF SUBSTITUTES
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 IMPACT OF COVID-19 ON THE GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET
  • 5.3.1 IMPACT ON SUPPLY CHAIN
  • 5.3.2 IMPACT ON KEY PLAYERS
  • 5.3.3 IMPACT ON DEMAND
• 5.4 QUANTITATIVE MARKET INSIGHTS
  • 5.4.1 NUMBER OF CPET METABOLIC CARTS BY REGION, 2022
  • 5.4.2 AVERAGE TESTS PERFORMED IN 2022, BY TYPE OF FACILITIES, BY REGION, 2022
• 5.5 QUALITATIVE CONSUMER ASSESSMENT
  • 5.5.1 DEMAND FOR CPET SOFTWARE IN MAJOR REGIONS
  • 5.5.2 AVERAGE TIME REQUIRED FOR INTERPRETING CPET TESTS, INCLUDING REPORTING.
  • 5.5.3 % CHANCES OF ADOPTION OF TECHNOLOGICAL ADVANCEMENTS SUCH AS SEMI-AUTOMATIC INTERPRETATION PROGRAM
  • 5.5.4 RANGE OF % PROFITS BY FACILITIES PERFORMING CPET TESTS
  • 5.5.5 % INVESTMENTS IN CPET SOFTWARE

6 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT

• 6.1 OVERVIEW
• 6.2 CPET METABOLIC CARTS
• 6.3 SOFTWARE

7 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, BY END USER

• 7.1 OVERVIEW
• 7.2 HOSPITALS & CLINICS
• 7.3 DIAGNOSTIC CENTERS
• 7.4 AMBULATORY CENTERS
• 7.5 OTHERS

8 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, BY REGION

• 8.1 OVERVIEW
• 8.2 NORTH AMERICA
  • 8.2.1 US
  • 8.2.2 CANADA
• 8.3 EUROPE
  • 8.3.1 GERMANY
  • 8.3.2 FRANCE
  • 8.3.3 UK
  • 8.3.4 ITALY
  • 8.3.5 SPAIN
  • 8.3.6 REST OF EUROPE
• 8.4 ASIA-PACIFIC
  • 8.4.1 CHINA
  • 8.4.2 INDIA
  • 8.4.3 JAPAN
  • 8.4.4 AUSTRALIA
  • 8.4.5 SOUTH KOREA
  • 8.4.6 REST OF ASIA-PACIFIC
• 8.5 REST OF THE WORLD
  • 8.5.1 MIDDLE EAST
  • 8.5.2 AFRICA
  • 8.5.3 LATIN AMERICA

9 COMPETITIVE LANDSCAPE

• 9.1 OVERVIEW
• 9.2 COMPETITIVE BENCHMARKING
• 9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET
• 9.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET
• 9.5 KEY DEVELOPMENT ANALYSIS
• 9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 9.6.1 PRODUCT/COMPANY LAUNCH/PRODUCT APPROVAL
  • 9.6.2 COLLABORATION/AGREEMENT
• 9.7 FINANCIAL MATRIX
  • 9.7.1 SALES (USD MILLION), 2021
  • 9.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2021

10 COMPANY PROFILES

• 10.1 SCHILLER AG
  • 10.1.1 COMPANY OVERVIEW
  • 10.1.2 FINANCIAL OVERVIEW
  • 10.1.3 PRODUCTS OFFERED
  • 10.1.4 KEY DEVELOPMENTS
  • 10.1.5 SWOT ANALYSIS
  • 10.1.6 KEY STRATEGIES
• 10.2 COSMED SRL
  • 10.2.1 COMPANY OVERVIEW
  • 10.2.2 FINANCIAL OVERVIEW
  • 10.2.3 PRODUCTS OFFERED
  • 10.2.4 KEY DEVELOPMENTS
  • 10.2.5 SWOT ANALYSIS
  • 10.2.6 KEY STRATEGIES
• 10.3 MGC DIAGNOSTICS CORPORATION
  • 10.3.1 COMPANY OVERVIEWS
  • 10.3.2 FINANCIAL OVERVIEW
  • 10.3.3 PRODUCTS OFFERED
  • 10.3.4 KEY DEVELOPMENTS
  • 10.3.5 KEY STRATEGIES
• 10.4 OXIGRAF, INC
  • 10.4.1 COMPANY OVERVIEW
  • 10.4.2 FINANCIAL OVERVIEW
  • 10.4.3 PRODUCTS OFFERED
  • 10.4.4 KEY DEVELOPMENTS
  • 10.4.5 KEY STRATEGIES
• 10.5 VYAIRE MEDICAL, INC
  • 10.5.1 COMPANY OVERVIEW
  • 10.5.2 FINANCIAL OVERVIEW
  • 10.5.3 PRODUCTS OFFERED
  • 10.5.4 KEY DEVELOPMENTS
  • 10.5.5 KEY STRATEGIES
• 10.6 CORTEX BIOPHYSIK GMBH
  • 10.6.1 COMPANY OVERVIEW
  • 10.6.2 FINANCIAL OVERVIEW
  • 10.6.3 PRODUCTS OFFERED
  • 10.6.4 KEY DEVELOPMENTS
  • 10.6.5 KEY STRATEGIES
• 10.7 KONINKLIJKE PHILIPS N.V.
  • 10.7.1 COMPANY OVERVIEW
  • 10.7.2 FINANCIAL OVERVIEW
  • 10.7.3 PRODUCTS OFFERED
  • 10.7.4 KEY DEVELOPMENTS
  • 10.7.5 SWOT ANALYSIS
  • 10.7.6 KEY STRATEGIES
• 10.8 HILL-ROM HOLDINGS, INC
  • 10.8.1 COMPANY OVERVIEW
  • 10.8.2 FINANCIAL OVERVIEW
  • 10.8.3 PRODUCTS OFFERED
  • 10.8.4 KEY DEVELOPMENTS
  • 10.8.5 KEY STRATEGIES
• 10.9 MEDEV MEDICAL DEVICES CORPORATION
  • 10.9.1 COMPANY OVERVIEW
  • 10.9.2 FINANCIAL OVERVIEW
  • 10.9.3 PRODUCTS OFFERED
  • 10.9.4 KEY DEVELOPMENTS
  • 10.9.5 SWOT ANALYSIS
  • 10.9.6 KEY STRATEGIES
• 10.10 GERATHERM MEDICAL AG
  • 10.10.1 COMPANY OVERVIEW
  • 10.10.2 FINANCIAL OVERVIEW
  • 10.10.3 PRODUCTS OFFERED
  • 10.10.4 KEY DEVELOPMENTS
  • 10.10.5 SWOT ANALYSIS
  • 10.10.6 KEY STRATEGIES

11 APPENDIX

• 11.1 REFERENCES
• 11.2 RELATED REPORTS